Biotecnologie Farmaceutiche 2014-2015 !"#$%&'%#()#*+,&-+#.+/)'0&+"-# # )1## !"#$%&'#(#)"%*+,-.,&%/0&1%* * 2"*3-%2%'$,*,)("*4$/5%'0* ! 2+(%3+4#5#6),/1%#789:## Biotecnologie Farmaceutiche 2014-2015 Corso di Laurea Magistrale (+2) in: • Biotecnologie farmaceutiche – Classe: LM-09 Biotecnologie Farmaceutiche 2014-2015 Presidente del CCS in Biotecnologie Farmaceutiche Barbara Gatto Direttore del Dipartimento di Scienze del Farmaco Manlio Palumbo Tutors Massimo Rosso Anna Fortuna Rappresentanti degli studenti Lorenzo Bonaguro Nicola Vajente ___________________________________________________________________ http://www.unipd.it/biotecnologie-farmaceutiche http://www.dsfarm.unipd.it/corsi/corsi-di-laurea-1/corso-di-laurea-magistrale-biotecnologie-farmaceutiche https://it-it.facebook.com/BiotecnologieFarmaceuticheUnipd Biotecnologie Farmaceutiche 2014-2015 Ordinamento attuale: Laurea Magistrale in Biotecnologie Farmaceutiche (LM-9): dall’A.A. 2008-2009 Laurea Specialistica in Biotecnologie Farmaceutiche (LS-9): dall’A.A. 2004-2005 Laurea Vecchio Ordinamento in Biotecnologie - Indirizzo Farmaceutico: dall’A.A. 2000-2001 Biotecnologie Farmaceutiche 2014-2015 Outline Perché Cosa Come Biotecnologie Farmaceutiche 2014-2015 Perchè Biotecnologie Farmaceutiche 2014-2015 Il segmento più rilevante del settore biotecnologico è quello relativo alle biotecnologie applicate alla salute dell’uomo (terapia, diagnostica e drug delivery), sia per la numerosità delle imprese sia per il numero degli addetti e l’entità degli investimenti in R&S, nonché i volumi di fatturato espressi. … questo settore include: • Terapeutici • Tecnologie e servizi per la drug discovery • Drug delivery • Tissue engineering • Diagnostica molecolare Rapporto sulle biotecnologie in Italia - Report 2011, by Assobiotec, Farmindustria, ICE, Ernst&Young Biotecnologie Farmaceutiche 2014-2015 http://assobiotec.federchimica.it/ Biotecnologie Farmaceutiche 2014-2015 =&'(9"-%&6! (* @]Ydl`[Yj]Zagl][`fgdg_q`YkYlj]e]f\gmkaehY[lgfe]]laf_l`]f]]\kg^hYla]flk&Alfglgfdq]f[gehYkk]k! e]\a[af]kl`YlYj]eYfm^Y[lmj]\mkaf_YZagl][`fgdg_a[Ydhjg[]kk$ZmlYdkg_]f]Yf\[]ddl`]jYha]k$! Adk]llgj]\]d^YjeY[gZagl][` Yf\lakkm]]f_af]]j]\hjg\m[lk&9dkgafAlYdqj]\Zagl][`akl`]kh]Yj`]Y\k]_e]flg^l`]]flaj]k][lgj$! oal`egj]l`Yf*,([gehYfa]kYf\Yfaf[j]Ykaf_fmeZ]jg^hjgb][lkY\\j]kkaf_\aY_fgkakYf\l`]jYhq$ o`a[`Yj]Yae]\Ylghlaearaf_l`]]flaj]hYl`oYqg^[Yj]Zgl`^jgeY[dafa[YdYf\][gfgea[hgaflg^na]o& !"#$%&'() *%+&,"-"&.%$"-/01&-2&-3%&.%,&#/2-%43&5%4-2.6&,%-"/$5&20&789:&"0,&;<.%&#/2-%43&42=;"0/%5&IK-.+6&H(LMJ F]ddËYeZalg\]dj]\Zagl][`adk]llgj]\]d^YjeY[gZagl][` Ad^g[mk\]dhj]k]fl]JYhhgjlgkmdd]aehj]k][`]kag[[mhYfg >%,&#/2-%43 ?@)A&>%;2.-B ?@)'&>%;2.hj]\geafYfl]$afl]jeafa\afme]jgaehj]k] /1!$ \]a^YjeY[aZagl][`$[agaehj]k]\]d^YjeY[g]Ydlj]Zagl][` !2-"$&#/2-%43 C<.%&#/2-%43 !2-"$&#/2-%43 C<.%&#/2-%43 ^YllmjYlg 1(!$Y\\]llaJK 1(!]\afn]klae]fla 0.!& \]d^YjeY[g$adk]_e]flghajad]nYfl]\]dj]\Zagl][`& #$%&'()*+),*%-./0'1 2"" 3"4 2"3 3"5 Adk]llgj]\]d^YjeY[gZagl][`[gklalmalg\Yim]dd]aehj]k][`] DY>a_mjY*&*\]na\]frY\]ddYjad]nYfrY\alYd]k]llgj] 6*7.8)7$(/*9'( :);<;34)%0880*/ :)3<35!)%0880*/ :);<;;2)%0880*/ :)3<3=")%0880*/ YddÌafl]jfg\]dj]\Zagl][`&?mYj\Yf\gYddYlahgdg_aY\aYra]f\Y$ kngd_gfgYllanald]_Yl]Yhjg\glla^YjeY[]mla[a$\jm_\]dan]jq$ 6*7.8)0/9'17%'/7)0/)>?@ :)3<!53)%0880*/ :)!;=)%0880*/ :)3<!42)%0880*/ :)!;;)%0880*/ d]aehj]k]\]d^YjeY[g[gfljaZmak[gfgafdYj_YhYjl]Yd^YllmjYlg l][fgdg_a]]k]jnarah]j\jm_\ak[gn]jq]nY[[afa LYZ]ddY*&)!& 1*!$Y\\]llaafJK5<23= /+!]afn]klae]fla /1!\]dk]llgj] 6*7.8)>?@)'%-8*A''1 5<!"5 3<"=" 3<"3; \]d^YjeY[gZagl][`& Adj]klg\]dj]\Zagl][`[gehj]f\]$gdlj]Ya[gke]la[a$dÌYj]Y\]a "<YlY`Yn]Z]]fj][laÕ]\lgeYc]kYehd][gehYjakgfhgkkaZd]& \aY_fgkla[a$[gehgklY\Yaehj]k]aeh]_fYl]hjaf[ahYde]fl] Ad[Yehagf]\aaehj]k]gh]jYflaf]ddgknadmhhg]n]f\alY f]ddYhjg\mragf]\a\akhgkalanae]\a[g%\aY_fgkla[aafnaljg AN<!$ L`]ÕjekY[lan]afZagl][`fgdg_qYhhda]\ Y[lanalqafl`]j]\Õ]d\&9kYdj]Y\q N81"+-/2(LNK2(K"$"6-)(;"-K0/%&5/2(O./%( %-(!.51)(!&1$%!(15-.)%(%-(>?@(-7(%!&( !"#!$"#!%&'(")(%!&(*+&,"-./(0&1+2(3&(1+&( %-()15&(1(7&3(<(3!"6!2(1/(3&$$(1/(9&")#( BioInItaly - 2014, \a^YjeY[aZagl][`egdlgjYhhj]k]flYlang\]dhYfgjYeY l]kl]e]lg\aZYkYlakm<F9'JF9h]jdY\aY_fgka$dYhjg_fgka by Assobiotec, Farmindustria, Ernst&Young %-%1$().59&+(-7(9"-%&6!(6-5*1)"&/A( oalf]kkaf_Yk`jafcaf_$o`a[`j]Ö][lk %!&(&4*+&//"-)(-7(%!&(-.%/%1)'")#(+&/.$%/( alYdaYfg\]dd]Zagl][fgdg_a]\]ddYkYdml]h]j[`adfme]jg\a ]dYhj]\aragf]\akh][aÕ[`]hYlgdg_a]&Afl]jeafa 9&/"'&/(+&*+&/&)%")#().5&+"61$$0(5-+&( %!&(&4%+&5&$0(6!1$$&)#")#(&6-)-5"6( %!1%(510(1+"/&(7+-5(%!&(7+."%7.$(/0)&+#0( aehj]k][`]kag[[mhYfg\a^YjeY[aZagl][`jYhhj]k]flYmfY \ahjg\glla'k]jnara$dÌYj]Y\]a\aY_fgkla[aka[YjYll]jarrYh]j2 %!1)(!1$7(-7(%!&(B%1$"1)(9"-%&6!(")'./%+02( 7+15&3-+8(%!1%(51)0(-7(-.+(5"6+-(1)'( -7(&)%+&*+&)&.+"1$(/8"$$/2(7-+31+'P$--8")#( imglYka_faÕ[YlanY\]ddÌafl]jgk]llgj] /1!&Jakh]llgYdd]*+0 hjg\glla2kljme]fla$eYl]jaYda\a[gfljgddg$cal]j]Y_]flah]jdY l`]qYdkgY[[gmfl^gjYka_faÕ[Yfl /51$$(*.+&(9"-%&6!(6-5*1)"&/(1+&(6-*")#( afn]kle]flkYf\k[a]flaÕ[]ph]jlak]$Ydkg aehj]k]aeha]_Yl]f]dk]llgj]j]\Zagl][`$af^Ylla$)00aehj]k] \aY_fgkla[Y *+-*-+%"-)(-7(%!&(%-%1$(%.+)-,&+(1)'(%!&( oal`$Yko]ddYkl`]\a^Õ[mdla]kl`]q +&5")'(./(%!1%(%!&+&("/(5.6!(3&(61)('-( "),&/%5&)%/(-7(%!&(&)%"+&(/&6%-+:( 6-)%").&(716")#(")(/-.+6")#(,&)%.+&(61*"%1$:( ( ")(-+'&+(%-(7.$$0(&4*$-"%(%!&("))-,1%"-)( ka\]\a[YfgY\Yllanalaf]j]flaYa^YjeY[aZagl][`$e]flj]ad k]jnara2\aY_fgkla[Yafnaljg$Y^Õllg\ahaYllY^gje]]l][fgdg_a] *-%&)%"1$(-7(B%1$"1)(9"-%&6!)-$-#"&/:( 2014-2015 j]klYfl]*)kag[[mhY\a\aY_fgkla[a]'g[gke]la[a& hjghja]lYja]h]jYllanal\aja[]j[Y& Biotecnologie Farmaceutiche C!&().59&+(-7(+&'(9"-%&6!(6-5*1)"&/("/( ;&0-)'(%!&"+(6-)%+"9.%"-)(")(%&+5/(-7( /$"#!%$0($-3&+(6-5*1+&'(%-(DEFGH(%!&($-//( "),&/%5&)%(1)'(+&,&).&/2(+&'(9"-%&6!( L`]lglYdfmeZ]jg^ÕjekY[lan]afl`] -7(&"#!%(6-5*1)"&/(I/"4(-7(3!"6!(3&+&(*.+&( [gehYfa]k`Yn]ka_faÕ[Yfldq_jgofl`]aj j]\Zagl][`Õ]d\ak*,) LYZd],&)!$ LYZ]ddY*&)%;Yeha\aYhhda[Yragf]%k]llgj]\]d^YjeY[gZagl][` >gfl]2]dYZgjYragfa=jfklQgmf_! 9"-%&6!(6-5*1)"&/J(!1/()-%(9&&)(-77/&%(90( *+-'.6%(*"*&$")&(1)'(!1,&(*+-,"'&'(%!&( QF@(-7(3!"6!("/(51'&(.*(-7(6-5*1)"&/( %!&(7-.+()&3(&)%+"&/(1)'(%!&(716%(%!1%(-)&( ]flj]hj]f]mjaYdYf\ÕfYf[aYd[geemfalq '&'"61%&'(&46$./",&$0(%-(!.51)(!&1$%!A( ;Yeha\aYhhda[Yragf] <]k[jaragf] -%!&+(6-5*1)0(!1/(&4*1)'&'("%/(9./")&//( 3"%!(1().59&+(-7(%+.&(/.66&//(/%-+"&/(<( %!&(+&51")")#(FR@(6-)/"/%/(-7(5.$%"P6-+&( !" Hjg\glla^YjeY[]mla[a !"#$%#&'(%)"*+,&)$)-.'/*0)1"'2'3456 >YjeY[agYdljaYhhjg[[al]jYh]mla[a$[ge]d]l]jYha]ZYkYl]km_]fag[]ddmd]$af[dmka2 Zagdg_a[a Zagdg_a[Ydk!2hjgl]af]ja[geZafYfla$Yfla[gjhaegfg[dgfYda$hjg\gllaZYkYlakmdd]l][fgdg_a] \]_daY[a\afm[d]a[a [gehgklaYZYkkgh]kgegd][gdYj] keYddegd][md]k!2^YjeY[aknadmhhYla$l]klYlagaf\ana\mYlae]\aYfl]e]lg\a[`] \ak[j]]faf_Zagl][` l]jYha]YnYfrYl]2^YjeY[aZagdg_a[aknadmhhYlaYlljYn]jkgdYl]jYhaY[]ddmdYj]kgeYla[Y$dYl]jYhaY_]fa[Y gdÌaf_]_f]jaYlakkmlYd]$mladarrYlakghjYllmllgh]jadljYllYe]flg\aeYdYlla]_]f]la[`]]\]_]f]jYlan]& NY[[afa N]f_gfgmladarrYlah]jdYhj]n]fragf]]dYl]jYhaY& KgfgnY[[afahjg\glla[gfZagl][fgdg_a] ÉnY[[afaja[geZafYflaÊ![`]h]je]llgfg\aakgdYj]ad_]f][`][g\aÕ[Y dYhjgl]afY\]dea[jgj_Yfakegaf_jY\g\aklaegdYj]dYjakhgklYaeemfalYjaY& <jm_\]dan]jq L][fgdg_a]h]jn]a[gdYj]a^YjeY[aYmfkalgkh][aÕ[ge]\aYfl]gllaearrYragf]\]ddgjgYkkgjZae]flg]\]ddYdgjg \akljaZmragf] eYl]jaYdaYnYfrYla$dahgkgea$Yfla[gjha$l]jYhaY[]ddmdYj]$][[&!& Im]klg[Yehg\aYhhda[Yragf]n]\]dgknadmhhg\ahjg\glla[`][gfkaklgfgafkakl]ea\ajadYk[ag[`]kgeeafakljYfg afeg\geajYlgad^YjeY[gkgdgafmfÌYj]Y\aja^]jae]flg\]d[gjhg h]j]k]ehagf]al]kkmla[Yf[]jgka!]h]jmfh]jag\g \al]ehg[gfljgddYlg& <jm_\ak[gn]jq Kafl]ka$gllaearrYragf]][YjYll]jarrYragf]\a\jm_[Yf\a\Yl]$knadmhhg\akY__a$Yllanal\ak[j]]faf_]nYda\Yragf] kma^YjeY[a& KaljYllY\amf[Yehg\aYhhda[Yragf][`]hj]n]\]kghjYllmllgdYn]f\alY\ak]jnara2 l][fa[`]\an]jaÕ[Y\]ddY^mfragfYdall]jYh]mla[Y\afmgn]egd][gd] l]klkmhaYllY^gje][]ddmdYjaaf_]_f]jarrYl]Y\`g[h]jk]_fYdYj]]n]flmYdaj]YragfaYhjg\glla[`aea[agZagdg_a[a kmhhgjlg[ge];gfljY[lJ]k]Yj[`Gj_YfarYlagf ;JG!& )* JYhhgjlgkmdd]Zagl][fgdg_a]\]dk]llgj]^YjeY[]mla[gafAlYdaYÆ*()* an experimental drug or standard of care. Each arm will operate independently and be powered to demonstrate overall survival as the primary endpoint. Interim progression-free survival would be used to determine whether an experimental drug progresses from phase 2 to 3. eral study arms in a single, ongoing, clinical trial. Another change is that testing patient DNA with next-generation sequencing can provide more diagnostic information than can be achieved with one test. This is a bold move away from testing each drug with its own companion diagnostic. accounted for only 7% of revenue generated by the top ten treatments worldwide in 2001, but made up 71% of that revenue in 2012. Over a similar period, biotech product sales more than quadrupled, financing of biotech research increased tenfold, and the amount invested in pharma-biotech research alliances increased sixfold. In fact, all parameters in the Tufts report point in the same direction: pharma has dramatically shifted its R&D strategy from an almost singular focus on small-molecule Box 1 First two drugs celebrate I-SPY2 graduation Table 1 The first five squamous cell lung cancer treatment arms chosen for the drugs in the early 1990s to a dominant focus on biotech products today. Driving the master protocol launch While the Friends of Cancer Research prepare to launch the Lung Cancer Master Protocol, transformation are biotech products’ novel sponsors of the landmark phase 2 I-SPY2 trial are celebrating the graduation of its first Company/location Compound Target mechanisms of action and ability to command two candidates, AbbVie’s veliparib andMEDI4736 Puma Biotechnology’s neratinib. Veliparib and MedImmune/Gaithersburg, Maryland mAb targeting programmed cell death high 1 prices, combined with the declining neratinib were the first two drugs to enter into the trial, suggesting it can deliver on its ligand patent lives of small-molecule drugs, the report promise of efficiently identifying whichAzd4547 patients respond to which drugs. Across the receptor tyrosine said. Biotechnology Industry Organization AstraZeneca/London Fibroblast growth factor Biologics have replaced small molecules as the Atlantic, in December, the European Union’s Innovative Medicines Initiative spokesperson Tracy Cooleyfocus says her organization kinase inhibitorunveiled a dominant of big pharma’s pipeline, and a agrees that the new growth of biotech €53 ($72.7)-million adaptive trial to test Alzheimer’s disease drug candidates. analysis fromhas thebeen Tufts Center for the Study Amgen/Thousand Oaks, California Rilotumumab A mAb directed against hepatocyte growth driven in part by those factors, though the shift has quantified “These trials are the wave of the future,” says Hope Rugo, a trial investigator and factor of Drug Development (Boston) “can be largely attributed to a natural evolution oncologist at the University San Francisco School of Medicine. 2012, about 40% of Genentech/S. San Franciscoof California Pictilisib Phosphoinositide-3 kinase inhibitor of the industry.”the phenomenon. InEmily Waltz all biotech products in clinical development The I-SPY2 trial, which launched in 2010, tests multiple drugs, from multiple Pfizer/New York Palbociclib A cyclin-dependent kinase (CDK)-4 and were being developed by big pharma, up from companies, in newly diagnosed breast (pd-0332991) cancer patients before they undergo surgery (Nat. CDK6 inhibitor Biotecnologie Farmaceutiche NEWS 2014-2015 IN brief It’s official: biologics are Biologics have replaced small molecules as the dominant focus of pharma’s darlings big pharma’s pipeline • In 2012, about 40% of all biotech products in clinical Biotechnol. 28, 383–384, 2010). Investigators use up to ten biomarker signatures mAb, monoclonal antibody. 15.2 % in 2000, according to Ron Evens, adjunct professor at the University of the to stratify patients. They also feed early efficacy data into an adaptive randomization IN theiranPacific words development were being developed byThedepending big pharma, up from in Stockton, California, who conducted of action ofenrolls a particular core innovation in the master protocol algorithm that patientscompound. into differentWithin treatment arms on how previous the study with Boston-based Tufts. And in an “This is among the even more metric, worststartling applications of biotech products accounted for only 7% of will revenue generated biotechnology. They AbbVie’s veliparib, a poly(ADP-ribose) polymerase inhibitor, graduated in triple-negative Each arm will operate independently trial. Another change is that testing patient by the increase top ten treatments worldwide in 2001, the use of toxic (HER2 negative, hormone receptor negative) patients, a particularly nonresponsive but made up 71% that revenue in 2012. and be powered to demonstrate overall DNA with next-generation sequencing can pesticides in of industrial population. An estimated 62% of patients receiving veliparib had a pathologic complete whilebiotech product sales Over a agriculture similar period, survival as the primary endpoint. Interim provide more diagnostic information than response—no detectable tumor at the time of surgery—compared with 26% of patients providing absolutely no more than quadrupled, financing of biotech progression-free survival would be used to can be achieved with one test. This is a bold receiving the standard of care, Rugo reported at the San Antonio Breast Cancer benefit to consumers.” research increased tenfold, and the amount determine whether an experimental drug move away from testing each drug with its Andrew Kimbrell, Symposium in December 2013. The most common adverse events were hematologic. invested in pharma-biotech research alliances executive director of the Center for In Food Safety, progresses from aphase 2 to 3. own companion diagnostic. Puma’s neratinib, multi-tyrosine-kinase inhibitor, graduated in HER2 positive, increased sixfold. fact, all parameters in the heavily criticizes the USDA’s recommendation hormone receptor–negative patients. Investigators will present pathologic complete Tufts report point in the same direction: pharma to deregulate Dow AgroSciences Enlist corn and has dramatically shifted its R&D strategy from response and adverse event data at a medical conference later this year. soybean, which combines resistance to three an almost singular focus on small-molecule Box 1 First two drugs celebrate I-SPY2 graduation QuantumLeap Healthcare Collaborative, who are coordinating the I-SPY2 trial, are herbicides, among them glyphosate and 2,4,D. drugs2014) in the early 1990s to a dominant talking with AbbVie and Puma about launching I-SPY3, an adaptive collaborative (Reuters, 3 January focus on biotech products today. Driving the Whiletothe Friends of Cancer Research to launch Lung Cancer Master Protocol, follow-on I-SPY2. “I-SPY3 will hope to be aprepare nimble way to movethe these agents relatively “We lock up our refrigerator. We lock up our are biotech products’ novel sponsors the 3,” landmark phase 2 at I-SPY2 trialtime are these celebrating the graduation quickly into a of phase says Rugo, “but the same agents might go in to of its firstfreezer. We locktransformation up the pantry.” Mark Greenberg mechanisms of action and ability to command company-sponsored I-SPY2 is still and testing five Biotechnology’s more monotherapyneratinib. or combinations two candidates,trials.” AbbVie’s veliparib Puma Veliparib and of Denver, a consultant to a hedge fund, whose high prices, combined with the declining a rare condition that treatments, and more arms added. drugs have out of the trial so deliver far. neratinib were the firstcan twobedrugs toNo enter into thedropped trial, suggesting it can on its son has Prader-Willi, patent lives of small-molecule drugs, the report results in uncontrollable hunger. Zafgen of Inpromise Europe, of theefficiently biomarker-driven Alzheimer’s disease trial is expected to enroll about identifying which patients respond to which drugs. Across the said. Biotechnology Industry Cambridge, Massachusetts, announced some Organization 1,500 patients. The project is a proof-of-concept trial that shares many of the I-SPY2 Atlantic, in December, the European Union’s Innovative Medicines Initiative unveiled apositive phase 2a results in this indication spokesperson Tracy Cooley says her organization features. It is part of the EU’s Framework Programme 7 and applications are due April 8. with its anti-obesity drug beloranib, a METAP2 agrees that the growth of biotech has been €53 ($72.7)-million adaptive trial to test Alzheimer’s disease drug candidates. Asher Mullard Ottawa, Ontario, Canada inhibitor. (New driven York Times, 14 January in part by those2014) factors, though the shift “These trials are the wave of the future,” says Hope Rugo, a trial investigator and “can be largely attributed to a natural evolution oncologist at the University of California San Francisco School of Medicine. of the industry.” Emily Waltz patients fare; the algorithm enrolls more patients to into treatment arms when positive each arm, patients would be randomized is that multiple agents will be tested in sev15.2 % in 2000 signals emerge, and fewer negative of signals an experimental drugwhen or standard care.emerge. eral study arms in a single, ongoing, clinical • biotech products accounted for only 7% of revenue generated by the top ten treatments worldwide in 2001, but made up 71% of that revenue in 2012 • pharma has dramatically shifted its R&D strategy from an almost singular focus on small-molecule drugs in the early 1990s to a dominant focus on biotech products today The I-SPY2 trial, which launched in 2010, tests multiple drugs, from multiple they undergo surgery (Nat. Biotechnol. 28, 383–384, 2010). Investigators use up to ten biomarker signatures to stratify patients. They also feed early efficacy data into an adaptive randomization algorithm that enrolls patients into different treatment arms depending on how previous patients fare; the algorithm enrolls more patients into treatment arms when positive signals emerge, and fewer when negative signals emerge. AbbVie’s veliparib, a poly(ADP-ribose) polymerase inhibitor, graduated in triple-negative (HER2 negative, hormone receptor negative) patients, a particularly nonresponsive population. An estimated 62% of patients receiving veliparib had a pathologic complete response—no detectable tumor at the time of surgery—compared with 26% of patients receiving the standard of care, Rugo reported at the San Antonio Breast Cancer Symposium in December 2013. The most common adverse events were hematologic. Puma’s neratinib, a multi-tyrosine-kinase inhibitor, graduated in HER2 positive, hormone receptor–negative patients. Investigators will present pathologic complete response and adverse event data at a medical conference later this year. QuantumLeap Healthcare Collaborative, who are coordinating the I-SPY2 trial, are talking with AbbVie and Puma about launching I-SPY3, an adaptive collaborative follow-on to I-SPY2. “I-SPY3 will hope to be a nimble way to move these agents relatively quickly into a phase 3,” says Rugo, “but at the same time these agents might go in to company-sponsored trials.” I-SPY2 is still testing five more monotherapy or combinations treatments, and more arms can be added. No drugs have dropped out of the trial so far. In Europe, the biomarker-driven Alzheimer’s disease trial is expected to enroll about 1,500 patients. The project is a proof-of-concept trial that shares many of the I-SPY2 features. It is part of the EU’s Framework Programme 7 and applications are due April 8. Asher Mullard Ottawa, Ontario, Canada companies, in newly diagnosed cancer patients before NATURE BIOTECHNOLOGY VOLUME 32breast NUMBER 2 FEBRUARY 2014 117 IN their words “This is among the worst applications of biotechnology. They will increase the use of toxic pesticides in industrial agriculture while providing absolutely no benefit to consumers.” Andrew Kimbrell, executive director of the Center for Food Safety, heavily criticizes the USDA’s recommendation to deregulate Dow AgroSciences Enlist corn and soybean, which combines resistance to three herbicides, among them glyphosate and 2,4,D. (Reuters, 3 January 2014) Biotecnologie Farmaceutiche Cosa NATURE BIOTECHNOLOGY VOLUME 32 NUMBER 2 FEBRUARY 2014 2014-2015 “We lock up our refrigerator. We lock up our freezer. We lock up the pantry.” Mark Greenberg of Denver, a consultant to a hedge fund, whose son has Prader-Willi, a rare condition that results in uncontrollable hunger. Zafgen of Cambridge, Massachusetts, announced some positive phase 2a results in this indication with its anti-obesity drug beloranib, a METAP2 inhibitor. (New York Times, 14 January 2014) 117 Biotecnologie Farmaceutiche 2014-2015 Laurea Magistrale afferente al Dipartimento di Scienze del Farmaco e alla Scuola di Medicina e Chirurgia Classe di Laurea: LM-9 CFU: 120 2 ANNI Laureato Magistrale in Biotecnologie Farmaceutiche Biotecnologie Farmaceutiche 2014-2015 Finalità BioFarm La finalità del Corso di Laurea Magistrale in Biotecnologie Farmaceutiche è di formare laureati magistrali con una conoscenza scientifica adeguata per un impiego nella ricerca farmaceutica accademica e industriale. L'organizzazione e le esigenze della ricerca farmaceutica sono notevolmente cambiate negli ultimi anni, sia per la scoperta e sviluppo di farmaci tradizionali “a piccole molecole”, sia per lo studio e sviluppo di biofarmaci, ovvero proteine ricombinanti ed anticorpi monoclonali di nuova concezione. Il ricercatore farmaceutico necessita non solo di un’approfondita conoscenza negli ambiti farmaceutici e tecnologici tipici dei biofarmaci, ma anche di un’approfondita preparazione in biologia molecolare, biochimica strutturale, ingegneria genetica e ingegneria proteica. Le figure professionali che operano nel campo della ricerca e produzione farmaceutica devono anche possedere, oltre a conoscenze biotecnologiche di base, anche le specifiche competenze tecniche e normative dedicate ai problemi relativi a ricerca, sviluppo, controllo e consulenza dei farmaci di nuova concezione. Biotecnologie Farmaceutiche 2014-2015 Finalità BioFarm Le aree di apprendimento peculiari del Corso di Laurea Magistrale che garantiscono la specificità rispetto ad altri corsi della stessa classe sono descrivibili come: “area biologica”, “area biofarmaceutica” e “area tecnologicoapplicativa”, cui appartengono insegnamenti appartenenti alle discipline biotecnologiche comuni, alle discipline di base applicate alle biotecnologie e alle discipline farmaceutiche. La formazione impartita mediante gli insegnamenti e i laboratori didattici del Corso di laurea è integrata da seminari e corsi brevi dedicati ad argomenti specialistici e innovativi delle biotecnologie, e completata dallo svolgimento di una tesi sperimentale in laboratori di ricerca presso l’Università di Padova o in laboratori pubblici e/o privati in Italia o all’estero, tramite convenzioni o progetti LLP/Erasmus. Biotecnologie Farmaceutiche 2014-2015 Il laureato in Biotecnologie Farmaceutiche dovrà possedere… …conoscenze e competenze nei settori red biotech: • Terapeutici: sviluppo di farmaci e altri approcci terapeutici, come le terapie basate su geni o cellule. • Tecnologie e servizi per la “drug discovery”: sintesi, ottimizzazione e caratterizzazione dei farmaci candidati, sviluppo di saggi e attività di screening e validazione sui farmaci. • Drug delivery: tecnologie per veicolare i farmaci ad un sito specifico mediante ottimizzazione dell’assorbimento e distribuzione del farmaco (materiali avanzati, liposomi, anticorpi, terapia cellulare, etc). • Diagnostica molecolare: test e metodi basati sul DNA/RNA per la diagnosi, prognosi e predisposizione ad una malattia, per l’analisi di meccanismi patogeni e per test di paternità (non sono considerati i classici approcci immuno-diagnostici). Biotecnologie Farmaceutiche 2014-2015 Come Biotecnologie Farmaceutiche 2014-2015 Tesi sperimentale •Sviluppo, 30 CFU dedicati allo svolgimento della tesi sperimentale in: analisi e meccanismo d’azione dei farmaci •Tecnologie di drug discovery •Formulazione •Biologia e drug delivery molecolare e strutturale •Dipartimenti dell’Università di Padova •Proteomica di ricerca pubblici e privati in Italia e all’estero •Immunochimica •Laboratori •Diagnostica •Laboratori di ricerca europei tramite progetti Erasmus (70%) Abilità acquisite (skills) ! Conoscenza e capacità di comprensione applicata ! Autonomia di giudizio e capacità critica ! Abilità comunicativa in italiano e in inglese ! Capacità di lavorare in team (capacità relazionali) ! Problem solving/problem setting ! Creatività ! Iniziativa Conoscenze e competenze Studio Biotecnologie Farmaceutiche 2014-2015 Manifesto BioFarm PRIMO ANNO 1. Basi Razionali dell’Attività dei Farmaci 7 CFU 2. Biochimica Strutturale 6 CFU 3. Biologia Molecolare 2 6 CFU 4. Chimica Organica e Analisi Farmaceutica Avanzate 7 CFU 5. Ingegneria Proteica 6 CFU 6. Farmacologia Molecolare e Sperimentale 10 CFU 6 CFU 8. Farmaci Biotecnologici 7 CFU 9. Delivery e Formulazione di Farmaci Biotecnologici 11 CFU 10. Diagnostica Microbiologica e Immunochimica 10 CFU 11. Corsi a scelta autonoma 8 CFU Attività “Altre” 6 CFU Tesi sperimentale 30 CFU 7. Metodologie Biochimiche e Proteomica SECONDO ANNO Biotecnologie Farmaceutiche 2014-2015 Come: 1. Insegnamenti aggiornati con la letteratura più recente 2. Lezioni in inglese: • insegnamenti curriculari in inglese • seminari in inglese da parte di docenti stranieri (TS Erasmus) !"#$%#&'()"'$'(*+#%#$ &*" '!" &!" %&" $)" $!#!($!##" %!" $!##($!#$" $!" $!#$($!#%" #!" !" $!#!($!##" $!##($!#$" $!#$($!#%" 3. Modalità di esame con ricerche bibliografiche, journal club, presentazioni degli studenti 4. Approccio critico alla scienza: non solo insegnare la teoria… 5. Attività culturali organizzate dagli studenti: Biotecnologie Farmaceutiche 2014-2015 Biotecnologie Farmaceutiche 2014-2015 Biotecnologie Farmaceutiche 2014-2015 !"#$%&'() 2014 JOB: Job Opportunities for Biotech Lorenzo Bonaguro Nicola Vajente Ilaria Gregorio Massimo Rosso Linda Zambolin Serena Genovese Anna Di Bona Nicolò Rozzino Alessandro Mantese Marta De Guglielmi laf_]Y[` %"#%(3#1( #'3"(85160129 afl`] 3"(=&&>,( $401%:&1%(%4( `ak;gmfljq& K[a]f[]! `]AlYdaYf f_dan]gfklY_]l`jgm_` fkhgjlaf_l`]hmZda[afl`]ogjd\ *&,)+2%(3#+*%#0%)+%,.*%*4/3#0&,)#+% kg[aYde]\aYkm[`Yk>Y[]Zggc o]_]lcfgod]\_]YZd]YZgmlgmj gea[k& k]]`goAlYdqoYkkm[``a_`dq ja]khYjla[ahYlaf_afl`akÕjkl ,.*%+879*0%#$%&(,):),)*'%,.&,% fljq$af[dm\af_akdYf\k Õjklg^ *%,6/*%#$%&(,):),)*'%,.&,%.&:*% *0'*%/893)(%&+-%,.&,%.&:*% %/&0,)()/&+,'%)+,*+,%,#%/0*/&0*% ^gddgo]\^gjk]n]f\Yqk$\ak[mkkagfkgfl`]nYjagmkk][lgjk #$%9)#,*(.+#3#265%,.*&,0*%/*0$#07&+(*'5%&0,%*4.)9),)#+'5% alaf]jYflk[a]flaÕ[dYZgjYlgja]k$l`]L]d]l`gfZagl][`o]]c$ #/*+%-&6'%#+%$&07'%&+-%0*'*&0(.%(*+,0*'%#$%,.*%CDE%&+-% 7&+65%7&+6%#,.*0%&(,):),)*'?% 9f\l`]j]Ìkfg\gmZll`Yll`]j]oYkkge]l`af_lg[Yhlmj] l`]Yll]flagfYf\aeY_afYlagfg^Yfqgf]oal`Yfgh]fYf\ )+F8)0)+2%7)+-? MfhghmdYjYkh][lkg^Zagl][`o]j]\]ZYl]\oal`k[`ggd (.)3-0*+%,.0#82.%G3&6%H*()-*5%&%2&7*%$#07&,%-*')2+*-% ,#/%$0&7*%-)'(8'')#+'%&9#8,%)7/&(,'5%0)'A'5%(#+(*0+'%&+-% Z]f]Õlkg^Y\nYf[]\j]k]Yj[`&L`]YaeoYklgk`go`go 9)#,*(.%(#++*(,'%,#%-&)36%3)$*%&+-%,#%.*3/%2&7*0'%&00):*%&,% (#7/0#7)'*'%)+%(#7/3*4%,*(.+)(&3%'89I*(,'?% af_kafj]k]Yj[`Yf\Yo]dd% 5%'#7*%&'/*(,'%#$%9)#,*(.%&0*% 65%&+-%,.)'%.&'%.*3-%9&(A%,.*% galoYkka_faÕ[Yfll`]AlYdaYf :*+,'? Abmkl`Yn]lgl`YfcYf\[gf_jYlmdYl]Yddl`gk]o`glggchYjl afl`akÕjkl]\alagfYf\lg]f[gmjY_]qgmYddlghj]hYj]^gj l`]f]pl]\alagfo`a[`oaddlYc]hdY[]ËZ]lo]]fG[lgZ]j.% &+-%"<5%<=">? fJge]oYk^gddgo]\Zq]n]flk$ [`afe]\a[af]$Zagj]Õf]ja]k$ ][gfgea[_jgol`&O]`Yn] !"#$"%&'()*%% +',-'#"-.(/'0'-"%(12-*3"4&* !"#$%#&'(%)"*+,&)$)-.'/*0)1"'2'3456 Biotecnologie Farmaceutiche 2014-2015 !" Tesi sperimentale • Dipartimenti dell Università di Padova • Centri interdipartimentali di ricerca (CRIBI) • Laboratori in Italia e all estero tramite convenzioni e progetti Erasmus (Mobilità internazionale laureati 2009: 61%) Biotecnologie Farmaceutiche 2014-2015 internazionalizzazione oltre la metà degli studenti partecipa a programmi di mobilità internazionale (oltre 60% degli studenti totali) (dato fornito in data 24/10/2013 dal Servizio Erasmus del Dipartimento): .4#:;9<=0>#?@A#B0#1/2BCB;D#5678198# #E=8FC98/#5678198#GC7F=1=0;H# "#:;9<=0>#?@A#B0#1/2BCB;D#5678198#-I4I4# #E=8FC98/#5678198#GC7F=1=0;H# $!!"# ,!"# +!"# *!"# '!"# (# (# ./0#1/2# (!"# '!"# &!"# %!"# %!$$-%!$%# %!$!-%!$$# ,# )!"# )'"# ),"# %!!,-%!$!# 3/24#5678198# $$# ,# )# $!"# !"# %!!,-%!$!# %!$!-%!$$# %!$$-%!$%# Rapporto di Riesame 2014 Biotecnologie Farmaceutiche 2014-2015 UNIVERSIDAD DE JAÉN www.pasteur-international.org www.ujaen.es www.epfl.ch ERASMUS PROJECTS www.unizh.ch www.ethz.ch www.uni-bonn.de www.unil.ch www.uni-jena.de Biotecnologie Farmaceutiche 2014-2015 Le abilità acquisite, ovvero conoscenza e capacità di comprensione applicata, autonomia di giudizio, capacità critica e abilità comunicativa sia in italiano che in inglese, permetteranno al laureato magistrale di possedere la preparazione professionale per l'impiego in laboratori di ricerca dedicati: • alla ricerca, progettazione, sviluppo, formulazione ed analisi di farmaci innovativi e biotecnologici; • alla ricerca e sviluppo nel campo delle tecnologie “omiche” (genomiche, proteomiche e bioinformatiche); • alla gestione e controllo di qualità in ambito biomedici, diagnostico e nutrizionale; • alla collaborazione con organizzazioni pubbliche o private dedite alla regolamentazione e documentazione nel settore biotecnologico-farmaceutico. Il corso di Laurea Magistrale inoltre fornisce la preparazione adeguata per l'accesso a Dottorati di Ricerca e Master Universitari di II livello in Italia e all’estero. Biotecnologie Farmaceutiche 2014-2015 ! Figura 1: Indagine sull'opinione degli studenti BTF 2012/2013. 1: Azione Didattica; 2: Soddisfazione Complessiva; 3: Aspetti Organizzativi Rapporto di Riesame 2014 Biotecnologie Farmaceutiche 2014-2015 Ammissione a BioFarm • Posti disponibili: 60 • a. Preimmatricolazione via web: CONTROLLARE GLI AVVISI DI AMMISSIONE su Uniweb – • b. Test d ingresso: Per essere ammessi è necessario superare una prova di ammissione, che consiste nello svolgimento di un tema su argomenti riguardanti aspetti generali delle biotecnologie e che permetterà alla Commissione esaminatrice di valutare l’adeguatezza della preparazione. – • Quando? Luglio 2014 Quando? 23 Settembre 2014 (CONTROLLARE GLI AVVISI) c. Immatricolazione in Segreteria come specificato negli AVVISI DI AMMISSIONE – Quando? Ottobre 2014 Biotecnologie Farmaceutiche 2014-2015 Ammissione a BioFarm a. Preimmatricolazione Requisiti curriculari per l ammissione a Biotecnologie Farmaceutiche: 1. laurea nelle classi L-2, L-13, L-27, L-SNT30 (270) o nelle classi 1, 12, 21, SNT3 (509) 2. laurea in classi diverse da quelle al punto 1. per tutti quei laureati (anche magistrali a ciclo unico) che abbiano ottenuto 100 CFU in esami dei Settori Scientifici CHIM, FIS, MAT, BIO, MED come dettagliato nel Regolamento Didattico. NB: presentare la domanda alle Segreterie Studenti con l elenco degli esami sostenuti Biotecnologie Farmaceutiche 2014-2015 Ammissione a BioFarm b. Test d ingresso Per essere ammessi è necessario superare una prova di ammissione, che consiste nello svolgimento di un tema su argomenti riguardanti aspetti generali delle biotecnologie e che permetterà alla Commissione esaminatrice e al candidato di valutare l’adeguatezza della preparazione e a predisporre attività di sostegno durante il primo semestre del primo anno. Biotecnologie Farmaceutiche 2014-2015 "!#$%$&! Sono stati analizzati i Dati da Alma Laurea (laureati 2012): il 79% degli studenti si dichiara soddisfatto del Corso di Studi completato; nell’anno precedente era stato calcolato il 75%. L’86% dei neolaureati contro l’81% dell’anno precedente si riscriverebbe allo stesso Corso di Studi frequentato, mentre il 14% frequenterebbe un altro Corso di Studi dello stesso Ateneo; nessuno si iscriverebbe allo stesso corso in un Ateneo diverso. Per quanto riguarda l’ingresso nel mondo del lavoro su un campione di 14 intervistati ad un anno dal conseguimento della laurea l’86% dichiara di avere un’occupazione che per il 43% riguarda la formazione post-laurea (dottorati di ricerca, borse, stage). A tre anni dalla laurea su 12 intervistati risulta che il 100% ha un’occupazione, di questi il 56% svolge attività di formazione post-laurea e tutti dichiarano di utilizzare le competenze acquisite con la laurea. Rispetto ai dati dell’intero Ateneo, emerge che la soddisfazione dei laureati per quanto riguarda l’organizzazione e la formazione prodotta dal corso di laurea, nonché l’utilizzo in ambito lavorativo delle competenze acquisite è decisamente superiore alla media. Rapporto di Riesame 2014 Biotecnologie Farmaceutiche 2014-2015 Sbocchi Professionali BTF !"#$%&'&() Le abilità acquisite, ovvero conoscenza e capacità di comprensione applicata, autonomia di giudizio, capacità critica e abilità comunicativa sia in italiano che in inglese, permetteranno al laureato magistrale di possedere la preparazione professionale per l'impiego in laboratori di ricerca dedicati: • alla ricerca, progettazione, sviluppo, formulazione ed analisi di farmaci innovativi e biotecnologici; • !"#$%&'()* alla ricerca e sviluppo nel campo delle tecnologie “omiche” !"#$%&'()= !"#$%&'()@ (genomiche, +,&-"."'/0%'1"20,."3,04'"2/%0.0'5"36078 />&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3 +,&-"."'/0%'1"20,."3,04'"2/%0.0'/$%0'5"36078 +,&-"."'/0%'3%"#",04'"2/%0.0'5"36078 />&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3 />&-%5A(5'"7&,".$&-$(B,-6%(C(D&;-+3 proteomiche e bioinformatiche); ?; <(; <(; • alla gestione e controllo di qualità in ambito >;biomedici, diagnostico e nutrizionale; • alla collaborazione con organizzazioni pubbliche o private<9; dedite alla <:; :>; 9:; regolamentazione e documentazione nel settore(9; biotecnologico-farmaceutico. ?; *(; =; Il corso di Laurea Magistrale inoltre fornisce la preparazione adeguata per l'accesso a ((; Dottorati di Ricerca e Master Universitari di II livello in Italia e all’estero. Q(E,"-45( Q(F54$"( Q(G$88&'"( Q(F$8,& DÌYfYdakah]jgja_af][gf^]jeY[ge]dY *"++$&,"-."(/0123(45''5($*#,565(,"-%$( $-("*7$%&(7$&%589(-"68"(8&*5(6%",%:;#<( ad*+[ge]khaf%g^^Y[[Y\]ea[g$ad)- [ge]ÕdaYd]\aemdlafYragfYd]$ad/[ge] khaf%g^^gkhaf%gmlaf\mkljaYd]$ad,( \Y^YjeY[]mla[YalYdaYfY$][ge]ad)* "77$"(&,$+$-5(4$=5,6"(/>$+;,"()?@3? Sbocchi Professionali BTF Q(E,"-45( Q(F54$"( Q(G$88&'"( Q(F$8,& (:; Q(H%",%:;#( QKhaf%g^^Y[[Y\]ea[g QKhaf%g^^gkhaf%gmlaf\mkljaYd] Q(>",*"85;%$8"($%"'$"-" Q(>$'$"'5(4$(*;'%$-".$&-"'5 Q(I'%,& B*$'$"(W&*"+-"(/0U3(5(X5-5%&(/)T3<( *5-%,5($'(-;*5,&(4$($*#,565(;7$8"%5(( -5''5(,5+$&-$(*5,$4$&-"'$(Q("-8&,"('$*$%"%&( 2014-2015 />$+;,"()?13? ;gfja^]jae]flgYddYdgjg\akljaZmragf] _]g_jYÕ[Y$d]aehj]k]Zagl][`\]d 8"*#$&-5(6&-&(#,5="'5-%5*5-%5( 8&-85-%,"%5(-5'(-&,4(5(-5'(85-%,&(O%"'$"?(( P"(P&*7",4$"(Q(&,*"$(6%&,$8"*5-%5('"( ,5+$&-5(8&-($'(#$R("'%&(-;*5,&(4$($*#,565( 7$&%589(/M)S3<(65+;$%"(4"(G$5*&-%5(/TU3<( V&68"-"(5(P".$&(/0@(&+-;-"3<(( Biotecnologie Farmaceutiche Y;"-%&("''"('&,&('&8"'$..".$&-5<($'(0U2(( 45''5($*#,565(7$&%589(9"(6545(";%&-&*"<( $'(TS2(Q('&8"'$.."%&("''Z$-%5,-&(4$(#",89$( !"#$%&'()> 9fYdakah]jdg[YdarrYragf]_]g_jYÔ[Y$aehj]k]Zagl][`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iotecnologie Farmaceutiche B=7875)C(=5D?5)*+,#.-;,/ !"#$%%"&'() .%7&87),F?F'75)G7&875) *"+,&-,&.,/+$.,&0$1&,&01,/2,0"%,&2"30,&-,&"00%,2"4,5/$6&.7--,8,.,5/$&0$1&9$:,5/$&!"#$%&'(&)*+#,*-.#$.(/,$0%(1(2#3$45 *+,/ Sbocchi Professionali BTF 9$:,5/,; <73$15&-,&,301$.$&#,5+$2=;; >301$.$&#,5+$2=?&& @"++71"+5;;; H5'7()*+,/ >301$.$&#,5+$2=?&& !< ,/8$.+,3$/+,&,/&9AB;;; C1$$/& #,5+$2= D=,+$& #,5+$2= 9$-& #,5+$2= C1$$/& #,5+$2= #$%&''()*+,-#./ ! 0 1 !2 0 45678795:5)*;,/ 0 1 1 0 1 0 K5%9LF ;585$%75 1 0 1 1 0 0 K(876F)*#./ 11 ;5=>5?75)*+,/ 0 ($- ! 0 ! !< 1 0 1 ! 0 3 A@ 1 1 @ 0 0 M7F=(?:F)*+,-;,/ 1! ($- !" 0 @ < !"3 @ 3 M&D875)*+,-#.-;,/ 1E! " 1 ($- .%7&87),F?F'75)G7&875) *+,/ 10 11 ! !2 A 0 +5%JFD?5)*+,-;,/ 2 @ H(=$5%J75) ;,/ *+,-#.- !< ! < 1I"!A 1 2 0 2 E0 0 1 3@ !3 1@ 2I22@ E0 K5%9LF " ! ! !2 1 K(876F)*#./ 1 1 0 0 0 M7F=(?:F)*+,-;,/ !" 3 11 ""E " 1 N%F?:7?()#8:()#J7DF 0 0 N(695?5)*+,/ @@ E!1 O=$%75)*;,/ 1 " ,588F)JP#(6:5 0 11 ,F?F:()*+,-;,/ 1A2 "1 !5+"%$ 0 0 0 " < H7D&%75)*+,/ 1@ 0 1A +797875)*+,-#./ 1 !@A 2 C1$$/& #,5+$2= ($- B=7875)C(=5D?5)*+,#.-;,/ H5'7()*+,/ >301$.$&#,5+$2=?&& < 1I"!A "--$++,&9AB ! H7D&%75)*+,/ D=,+$& 9$-& C1$$/& 2 D=,+$& 0 9$-& #,5+$2= #,5+$2= #,5+$2= #,5+$2= #,5+$2= H(=$5%J75) *+,-#.3@ !3 0 ;,/ 1! 0 0 23 9$-& #,5+$2= EE 11 < 1 !2 ($1 1 1< 1 1 ($" ! 1 2 12 E'F E2 1I!!2 A0 !I1AA 10 1 < E GF 1" 0 "@E 0 !1 1 E2 " 1E! " 12 1 ! HE " "< 0 !" !@ 110 1 @ 2" 1< 3!3 1@1 0 13 0 0 1A< 1@2 H(IHH 1 1 < 1 0 2 11 @ ! !@ 2 +797875)*+,-#./ < 1 ! 110 1 " [gfaf\a[Yragf]\]a[dmkl]j%KN K[a]fr]\]ddYNalY!%;N ;`aea[YN]j\]!%9> 9_jg%^gg\!Ç[mag_faJ]_agf]hYjl][ahY 0 2A 2 ($"@ !@ 1 "" [gehj]k]d]aehj]k]emdla%[gj] !!!"#$"%#&#'$#"(#") 0 2< ($0 1!< 2 !2 N%F?:7?()#8:()#J7DF 1 1 1 1 0 0 ! N(695?5)*+,/ !2 2 < 3!3 ! 0 O=$%75)*;,/ 1 1 0 0 1 0 ,588F)JP#(6:5 0 1 1 0 ! 12 E ! 1A< E'F GF HE H(IHH 1 0 A 20! ! 0 <03 ! ($- 0 11 0 0 ($- ($- 0 @ @ << E 0 23< JJK EIH J(HLJ JJE EL F()'H " [gfaf\a[Yragf]\]a[dmkl]j%KN K[a]fr]\]ddYNalY!%;N ;`aea[YN]j\]!%9> 9_jg%^gg\!Ç[mag_faJ]_agf]hYjl][ahY "" [gehj]k]d]aehj]k]emdla%[gj] !" !!!"#$"%#&#'$#"(#") 6,*(73&0%.8(*)93$.(0#$#(0%*%.(%,*(.(:,#;#%#,.( <&))*(9#0%.%3-.#$&(<&)(=)30%&,(6&9$#)#4.9#( >*-.#$*)&(?9.&$-&(<&))*(@.%*(ABC?/CD B*(6*+&))*(EDE(&F.<&$-.*(.(:,.$9.:*).(<*%.(<.( 0.$%&0.(<&)(0&%%#,&(+.#%&9G(:&,(#4$.(,&4.#$&( alYdaYfY$af^mfragf]\]ak]_m]flahYjYe]lja2 fme]jg\aaehj]k]$^YllmjYlg$afn]klae]fla .$(H1?8($3;&,#(<.(*<<&%%.(.$(H1?D !E 2I22@ 0 +5%JFD?5)*+,-;,/ !5+"%$ 0 ! E0D=,+$& #,5+$2= M&D875)*+,-#.-;,/ ,F?F:()*+,-;,/ 2 @ 1 0 11 1@ 1 !1 ($- 0 0 < "20 1 2014-2015 6,*(73&0%.8(*)93$.(0#$#(0%*%.(%,*(.(:,#;#%#,.( E 1! <&))*(9#0%.%3-.#$&(<&)(=)30%&,(6&9$#)#4.9#( 10 A >*-.#$*)&(?9.&$-&(<&))*(@.%*(ABC?/CD B*(6*+&))*(EDE(&F.<&$-.*(.(:,.$9.:*).(<*%.(<.( < 0 0.$%&0.(<&)(0&%%#,&(+.#%&9G(:&,(#4$.(,&4.#$&( ! 0 alYdaYfY$af^mfragf]\]ak]_m]flahYjYe]lja2 "0 12 fme]jg\aaehj]k]$^YllmjYlg$afn]klae]fla .$(H1?8($3;&,#(<.(*<<&%%.(.$(H1?D ILG FKF !"##$%&$'()**+',-$&+./$*$0-+'-/'1&"*-"'2'3456 >&))*(6*+&))*(EDJ8(4).(0%&00.(<*%.(0#$#( km\\anaka[gfja^]jae]flgYalj]( :,.$9.:*).(0&%%#,.(<.(*::).9*-.#$&(!,&<( +.#%&9G8(4,&&$(+.#%&9G(&(KG.%&(+.#%&9G5( $&.(73*).(#:&,*$#()&(.;:,&0&(.%*).*$&L( *++.*;#(.$#)%,&(.$<.9*%#(.$(73*)&(<&.(%,&( 9)30%&,(0#:,*9.%*%.()&(0.$4#)&(H&4.#$.(( 0#$#(9#.$F#)%&D Biotecnologie Farmaceutiche !" C1$ #,5+ 2014-2015 !"##$%&$'()**+',-$&+./$*$0-+'-/'1&"*-"'2'3456 Rapporto sulle biotecnologie del settore farmaceutico in Italia - 2012, by Assobiotec, Farmindustria, Ernst&Young 0 ($ E 1 2 ( 1 ! E JJ Biotecnologie Farmaceutiche 2014-2015 Docenti Antonella Caputo antonella.caputo@unipd.it Barbara Gatto barbara.gatto@unipd.it !"#$%&'(&")*"*'+*"#$%&,-&")*"*./"012,0)3' Barbara Spolaore barbara.spolaore@unipd.it !")&"$%%*'4*1/)&'+*")&"$%%*,5*1/)&./"012,0)3' 6*78*7*'9*))&'+8*78*7*,#*))&./"012,0)3' Chiara Bolego chiara.bolego@unipd.it 6*78*7*':1&%*&7$'+8*78*7*,;1&%*&7$./"012,0)3''' Dorianna Sandonà dorianna.sandona@unipd.it 4<0*7*'6&%$#&'+5<0*7*,8&%$#&./"012,0)3' =&70*""*':*"2&">'+2&70*""*,;*"2&"*./"012,0)3' Gianfranco Pasut gianfranco.pasut@unipd.it 90*"-7*"5&'?*;/)'+#0*"-7*"5&,1*;/)./"012,0)3' Lisa90&7#0*'@0&%&'+#0&7#0*,A0&%&./"012,0)3''' Dalla Via lisa.dallavia@unipd.it @&"05*'@&")&1&%0'+A&"05*,A&")&1&%0./"012,0)3' Monica Montopoli monica.montopoli@unipd.it ?*)70B0*'?&%C$70"&'=$'D*/7$)&'+1*)70B0*,1&%C$70"&2$%*/7$)&./"012,0)3' Patrizia Polverino De Laureto patrizia.polverinodelaureto@unipd.it ?*&%&':570A0"'+1*&%&,;570A0",/"012,0)3' :)$-*"&':*%A*;&'+;)$-*"&,;*%A*;&./"012,0)3' Marcella Bonchio marcella.sbonchio@unipd.it :/;*""*'@*"27/BB*)&'+;/;*""*,A*"27/BB*)&./"012,0)3''' Stefano Salmaso stefano.salmaso@unipd.it Susanna Mandruzzato susanna.mandruzzato@unipd.it Rappresentanti degli studenti Tutors Lorenzo Bonaguro: lorenzobonaguro@gmail.com Anna Fortuna: anna.fortuna24@gmail.com Nicola Vajente: nicolav.91@gmail.com Massimo Rosso: red.max.91@gmail.com
© Copyright 2024 Paperzz